drugset / Trial / NCT05872958

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

NCT05872958

Phase 1 Completed 98 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindOther

Summary

This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular \[IM\] injection and Intravenous \[IV\] infusion).

Timeline

Start
2023-05-19
Primary completion
2024-08-20
Completion
2024-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Sipavibart Monoclonal antibody Intramuscular

Indications